Literature DB >> 2021797

Final report on the second British Institute of Radiology fractionation study: short versus long overall treatment times for radiotherapy of carcinoma of the laryngo-pharynx.

G Wiernik, C J Alcock, T D Bates, J M Brindle, J F Fowler, W R Gajek, S Goodman, J L Haybittle, J M Henk, J W Hopewell.   

Abstract

The second British Institute of Radiology trial of dose fractionation in radiotherapy compared two groups of prospectively randomized patients with squamous carcinoma of the laryngo-pharynx; one group was treated in a short (less than or equal to 4 weeks) and the other in a long (greater than 4 weeks) overall time. Treatment in any one centre could be given, with no planned gap in the course of treatment, either as a conventional, daily (5 fractions per week regime) or as 3 fractions per week. A total of 611 patients were allocated to treatment, of whom nine have had to be excluded from the analysis for a lack of information. Patients were admitted to the trial from January 1976 to December 1985 and were followed up for a maximum of 10 years and a minimum of 3 years. A reduction in total dose was made for use in the short compared with the long treatment regime. This reduction in total dose varied between 18% and 22% depending on whether 5 fractions or 3 fractions per week regimes were used. Overall, no statistically significant differences have been found between the two arms of the trial. The patients treated with 5 fractions per week in a short overall treatment time showed fewer late normal tissue effects. An analysis based on stratification by age, stage and anatomical site gave a relative risk (short/long overall treatment time) for deaths of 1.23 with a 95% confidence interval from 0.96 to 1.59. Analyses stratified for stage and site gave relative risks with 95% confidence intervals of 1 x 10 (0.84-1.44) for local recurrences/tumour persistence, and 1.01 (0.70-1.45) for laryngectomies.

Entities:  

Mesh:

Year:  1991        PMID: 2021797     DOI: 10.1259/0007-1285-64-759-232

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  5 in total

1.  Radiotherapy for T1a glottic cancer: the influence of smoking cessation and fractionation schedule of radiotherapy.

Authors:  Abrahim Al-Mamgani; Peter H van Rooij; Robert Mehilal; Gerda M Verduijn; Lisa Tans; Stefan L S Kwa
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-25       Impact factor: 2.503

Review 2.  Hyperfractionated or accelerated radiotherapy for head and neck cancer.

Authors:  Bertrand Baujat; Jean Bourhis; Pierre Blanchard; Jens Overgaard; Kian K Ang; Michelle Saunders; Aurélie Le Maître; Jacques Bernier; Jean Claude Horiot; Emilie Maillard; Thomas F Pajak; Michael G Poulsen; Abderrahmane Bourredjem; Brian O'Sullivan; Werner Dobrowsky; Hliniak Andrzej; Krzystof Skladowski; John H Hay; Luiz Hj Pinto; Karen K Fu; Carlo Fallai; Richard Sylvester; Jean Pierre Pignon
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

3.  SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial.

Authors:  David L Schwartz; Alan Sosa; Stephen G Chun; Chiuxiong Ding; Xian-Jin Xie; Lucien A Nedzi; Robert D Timmerman; Baran D Sumer
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

4.  Online dosimetric evaluation of larynx SBRT: A pilot study to assess the necessity of adaptive replanning.

Authors:  Weihua Mao; Timothy Rozario; Weiguo Lu; Xuejun Gu; Yulong Yan; Xun Jia; Baran Sumer; David L Schwartz
Journal:  J Appl Clin Med Phys       Date:  2016-12-22       Impact factor: 2.102

5.  Three-week hypofractionated radiotherapy in early glottic cancer-a single institution retrospective study.

Authors:  Arun Sankar Sudha; Ravikumar Rejnish Kumar; Milan Anjanappa; Cessal Thomas Kainickal; Aleyamma Mathew; Ramadas Kunnambath
Journal:  Ecancermedicalscience       Date:  2022-05-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.